Sarepta Therapeutics (SRPT) Other Non-Current Liabilities (2012 - 2026)

Sarepta Therapeutics' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 96.53% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 96.53% YoY), while the FY2025 annual figure was $1.5 million, down 96.77% from the prior year.
• Other Non-Current Liabilities was $1.6 million for Q1 2026 at Sarepta Therapeutics, up from $1.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $48.2 million in Q2 2024 to a low of $1.4 million in Q3 2025.
• Historically, Other Non-Current Liabilities has averaged $32.9 million across 5 years, with a median of $38.1 million in 2023.
• Biggest YoY gain for Other Non-Current Liabilities was 530.15% in 2025; the steepest drop was 97.04% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $36.9 million in 2022, then climbed by 3.25% to $38.1 million in 2023, then advanced by 24.41% to $47.4 million in 2024, then slumped by 96.77% to $1.5 million in 2025, then climbed by 7.72% to $1.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.6 million (Q1 2026), $1.5 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.